Retrospective Analysis of Genomic Landscape of ALK Positive NSCLC Prior to Ceritinib, and at Disease Progression Following Ceritinib
Phase of Trial: Phase IV
Latest Information Update: 21 Feb 2017
At a glance
- Drugs Ceritinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 16 Feb 2017 Planned End Date changed from 1 Apr 2019 to 30 Apr 2019.
- 16 Feb 2017 Planned primary completion date changed from 1 Apr 2019 to 30 Apr 2019.